Resilience, a US-based developer of medical manufacturing technology, emerged from stealth yesterday with over $800m in funding from investors including GV, a subsidiary of internet and technology group Alphabet.
GV participated in a recently closed $750m series B round co-led by Arch Venture Partners and 8VC and also backed by fellow venture capital firm New Enterprise Associates and unnamed pharmaceutical companies, public mutual funds, foundations, family offices and pension funds.
Founded earlier this year and also known as National Resilience, Resilience is developing technologically advanced pharmaceutical manufacturing facilities that will help therapeutics developers concentrate more capital on drug discovery activities.
The technology is intended to allow gene and cell therapies, vaccines, proteins and viral vectors to be produced quickly and safely at scale.
The startup intends to bring more than 750,000 square feet of operating space online over the next year and will also offer drug chain development and supply chain management services.
Rahul Singhvi, co-founder and CEO of Resilience, said: “Our aim with Resilience is to improve manufacturing of breakthrough medicines so that they are more accessible to patients and to foster scientific innovation that makes new modalities of medicine possible.
“By providing improved process platforms and the highest quality manufacturing network, Resilience has been designed to help society meet the challenges of tomorrow, whether that is the next pandemic or high demand for a great new medicine.”
Resilience’s co-founder and chairman is Robert Nelsen, a managing director at Arch Venture Partners, and 8VC was also described as a co-founder. GV general partner David Schenkein has taken a board observer position in connection with its investment.
Although they have not been confirmed as investors, Resilience’s board of directors includes Allen & Company managing director Bob Kerrey and In-Q-Tel CEO Christopher Darby.
